FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017449832> ?p ?o ?g. }

• W2017449832 endingPage "1337" @default.
• W2017449832 startingPage "1331" @default.
• W2017449832 abstract "The aim of this study was to investigate the clinical activity and toxicity of a modified PVB regimen (cisplatin, vinblastine and bleomycin) in patients with advanced or recurrent, pure granulosa cell tumours (GCTs) or mixed granulosa-theca cell tumours (GTCTs). The PVB regimen consisted of cisplatin (P) 20 mg/m2 intravenous (i.v.) days 1-5, vinblastine (V) 0.15 mg/kg i.v. days 1-2 and bleomycin (B) 30 mg i.v. on day 2, and 15 mg on day 15, for 28 days. 38 eligible patients were entered in this trial. Prior to PVB all patients underwent surgery and 13 received postoperative radio- or other prior chemotherapy. The median number of PVB cycles was 4 in both groups. In the group of 25 patients who had received prior surgery only, 7 and 6 patients had complete and partial responses, respectively (response rate: 52%, 95% confidence limits: 31.3-72.2%). At a median follow-up of 39 months, 6 patients were alive with no evidence of disease, 6 were alive with disease, 12 died due to malignant disease and 1 died due to intercurrent disease. The median time to progression was 13.9 months. The median survival was 25.4 months. 3-year survival was 49% (95% confidence limits: 29-69%). In the group of 13 patients who had previously received postoperative radio- or chemotherapy, 5 complete and 5 partial responses were observed on PVB (response rate: 77%, 95% confidence limit: 46.2-95.0%). At a median follow-up of 50 months, 6 patients were still alive, only 1 without evidence of disease, 6 died due to malignant disease and 1 died due to intercurrent disease. The median time to progression was 19.3 months. The median duration of survival was 41.1 months. Accompanying toxicity was distributed in a similar pattern for both groups. Severe toxicity was mainly documented as haematological toxicity, nausea/vomiting and alopecia. Furthermore cisplatin-related peripheral neurotoxicity and mild/moderate signs of bleomycin-related pulmonary toxicity were observed. The present data confirm the therapeutic activity of the PVB regimen in advanced/recurrent GCTs. The response rate was moderately high compared with previous studies, with a median duration of response of 20 months for both groups." @default.
• W2017449832 created "2016-06-24" @default.
• W2017449832 creator A5000228515 @default.
• W2017449832 creator A5007067879 @default.
• W2017449832 creator A5007986153 @default.
• W2017449832 creator A5037599440 @default.
• W2017449832 creator A5049383880 @default.
• W2017449832 creator A5058535647 @default.
• W2017449832 creator A5084194739 @default.
• W2017449832 date "1999-09-01" @default.
• W2017449832 modified "2023-10-16" @default.
• W2017449832 title "Cisplatin (P), vinblastine (V) and bleomycin (B) combination chemotherapy in recurrent or advanced granulosa(-theca) cell tumours of the ovary. An EORTC gynaecological cancer cooperative group study" @default.
• W2017449832 cites W1584870901 @default.
• W2017449832 cites W1812754985 @default.
• W2017449832 cites W1861752925 @default.
• W2017449832 cites W1981514540 @default.
• W2017449832 cites W1983503169 @default.
• W2017449832 cites W1987880828 @default.
• W2017449832 cites W1991251856 @default.
• W2017449832 cites W2007619070 @default.
• W2017449832 cites W2014974631 @default.
• W2017449832 cites W2018397776 @default.
• W2017449832 cites W2027097780 @default.
• W2017449832 cites W2028221132 @default.
• W2017449832 cites W2043999231 @default.
• W2017449832 cites W2061596207 @default.
• W2017449832 cites W2072391170 @default.
• W2017449832 cites W2076475744 @default.
• W2017449832 cites W2085254107 @default.
• W2017449832 cites W2087561211 @default.
• W2017449832 cites W2156260710 @default.
• W2017449832 cites W2156382003 @default.
• W2017449832 cites W2167805334 @default.
• W2017449832 cites W2310175211 @default.
• W2017449832 cites W2408989594 @default.
• W2017449832 doi "https://doi.org/10.1016/s0959-8049(99)00142-2" @default.
• W2017449832 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10658523" @default.
• W2017449832 hasPublicationYear "1999" @default.
• W2017449832 type Work @default.
• W2017449832 sameAs 2017449832 @default.
• W2017449832 citedByCount "52" @default.
• W2017449832 countsByYear W20174498322012 @default.
• W2017449832 countsByYear W20174498322013 @default.
• W2017449832 countsByYear W20174498322014 @default.
• W2017449832 countsByYear W20174498322015 @default.
• W2017449832 countsByYear W20174498322016 @default.
• W2017449832 countsByYear W20174498322017 @default.
• W2017449832 countsByYear W20174498322020 @default.
• W2017449832 countsByYear W20174498322021 @default.
• W2017449832 countsByYear W20174498322022 @default.
• W2017449832 countsByYear W20174498322023 @default.
• W2017449832 crossrefType "journal-article" @default.
• W2017449832 hasAuthorship W2017449832A5000228515 @default.
• W2017449832 hasAuthorship W2017449832A5007067879 @default.
• W2017449832 hasAuthorship W2017449832A5007986153 @default.
• W2017449832 hasAuthorship W2017449832A5037599440 @default.
• W2017449832 hasAuthorship W2017449832A5049383880 @default.
• W2017449832 hasAuthorship W2017449832A5058535647 @default.
• W2017449832 hasAuthorship W2017449832A5084194739 @default.
• W2017449832 hasConcept C126322002 @default.
• W2017449832 hasConcept C126894567 @default.
• W2017449832 hasConcept C141071460 @default.
• W2017449832 hasConcept C2776232574 @default.
• W2017449832 hasConcept C2776694085 @default.
• W2017449832 hasConcept C2777132456 @default.
• W2017449832 hasConcept C2778239845 @default.
• W2017449832 hasConcept C2781413609 @default.
• W2017449832 hasConcept C71924100 @default.
• W2017449832 hasConcept C90924648 @default.
• W2017449832 hasConceptScore W2017449832C126322002 @default.
• W2017449832 hasConceptScore W2017449832C126894567 @default.
• W2017449832 hasConceptScore W2017449832C141071460 @default.
• W2017449832 hasConceptScore W2017449832C2776232574 @default.
• W2017449832 hasConceptScore W2017449832C2776694085 @default.
• W2017449832 hasConceptScore W2017449832C2777132456 @default.
• W2017449832 hasConceptScore W2017449832C2778239845 @default.
• W2017449832 hasConceptScore W2017449832C2781413609 @default.
• W2017449832 hasConceptScore W2017449832C71924100 @default.
• W2017449832 hasConceptScore W2017449832C90924648 @default.
• W2017449832 hasIssue "9" @default.
• W2017449832 hasLocation W20174498321 @default.
• W2017449832 hasLocation W20174498322 @default.
• W2017449832 hasOpenAccess W2017449832 @default.
• W2017449832 hasPrimaryLocation W20174498321 @default.
• W2017449832 hasRelatedWork W1998284678 @default.
• W2017449832 hasRelatedWork W2059001202 @default.
• W2017449832 hasRelatedWork W2059297796 @default.
• W2017449832 hasRelatedWork W2059965093 @default.
• W2017449832 hasRelatedWork W2070759546 @default.
• W2017449832 hasRelatedWork W2405657748 @default.
• W2017449832 hasRelatedWork W2415487830 @default.
• W2017449832 hasRelatedWork W2423822519 @default.
• W2017449832 hasRelatedWork W2443690542 @default.
• W2017449832 hasRelatedWork W3134705028 @default.
• W2017449832 hasVolume "35" @default.
• W2017449832 isParatext "false" @default.
• W2017449832 isRetracted "false" @default.
• W2017449832 magId "2017449832" @default.

• next